Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
Novartis Institutes for BioMedical Research · Novartis (Switzerland) · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
634
total citations
- FWCI
- 30.74
- Percentile
- 100%
- References
- 95
Citations per year
Authors
5- EWEllen WeisbergCorresponding
- PWPaul W. Manley
Novartis Institutes for BioMedical Research, Novartis (Switzerland)
- SWSandra W. Cowan‐Jacob
Novartis Institutes for BioMedical Research, Novartis (Switzerland)
- AHAndreas Hochhaus
University Medical Centre Mannheim, Medizinische Fakultät Mannheim
- JDJames D. Griffin
Harvard University, Dana-Farber Cancer Institute
Topics & keywords
Topics
Keywords
- Chronic myeloid leukaemia
- Imatinib
- Cancer research
- Medicine
- breakpoint cluster region
- Myeloid leukemia
- Internal medicine
- Receptor
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.